Breaking News

Over a month ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
ORGS Orgenesis $5.17 -0.03 (-0.58%) , CYAD Celyad $21.35 -0.15 (-0.70%) … 08:37 12/13/18 12/13 08:37 12/13/18 08:37 Conference/Events	William Blair to hold a conference » Biotech Focus Day Series:… Biotech Focus Day Series: Cell and Gene Therapy Manufacturing Conference will be held in New York on December 13. ORGS Orgenesis $5.17 -0.03 (-0.58%) CYAD Celyad $21.35 -0.15 (-0.70%) LOGC LogicBio Therapeutics $12.31 -1.37 (-10.01%) RCKT Rocket Pharmaceuticals $15.94 1 (6.69%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Dec
CYAD Celyad $26.85 -0.85 (-3.07%) 19:25 12/03/18 12/03 19:25 12/03/18 19:25 Conference/Events	Celyad to host webcast » Management holds a… Management holds a webcast to review data presented at the American Society of Hematology (ASH) Annual Meeting on December 3 at 11:30 pm. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Dec 10 Dec
CYAD Celyad $27.70 -0.12 (-0.43%) 07:55 12/03/18 12/03 07:55 12/03/18 07:55 Conference/Events	Celyad to host webcast » Management holds a… Management holds a webcast to review data presented at the American Society of Hematology (ASH) Annual Meeting on December 3 at 11:30 pm. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Dec 10 Dec
CYAD Celyad $27.82 2.94 (11.82%) 05:14 11/30/18 11/30 05:14 11/30/18 05:14 Hot Stocks	Celyad doses first mCRC patient in Phase 1 alloSHRINK trial » Celyad announced the… Celyad announced the injection of the first patient in the Phase 1 alloSHRINK trial evaluating the company's non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastatic colorectal cancer. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Dec 03 Dec 10 Dec
CYAD Celyad $24.88 (0.00%) 06:07 11/28/18 11/28 06:07 11/28/18 06:07 Conference/Events	Celyad to host webcast » Management holds a… Management holds a webcast to review data presented at the American Society of Hematology (ASH) Annual Meeting on December 3 at 11:30 pm. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Dec 03 Dec 10 Dec

CYAD Celyad $24.88 (0.00%) , BLUE Bluebird Bio $122.91 -5.47 (-4.26%) … 10:25 11/27/18 11/27 10:25 11/27/18 10:25 Conference/Events	William Blair biotech analysts to hold an analyst/industry conference call » Biotech Analysts, along… Biotech Analysts, along with Dr. Marco Davila of Moffitt Cancer Center, discuss the development of cell therapies in hematological malignancies on an Analyst/Industry conference call to be held on November 27 at 11 am. CYAD Celyad $24.88 (0.00%) BLUE Bluebird Bio $122.91 -5.47 (-4.26%) NVS Novartis $88.01 -0.99 (-1.11%) GILD Gilead $66.48 -0.48 (-0.72%) CELG Celgene $67.52 -0.49 (-0.72%) AUTL Autolus Therapeutics $39.20 -1.37 (-3.38%) ALLO Allogene Therapeutics $27.20 -0.39 (-1.41%) CLLS Cellectis $20.92 -0.37 (-1.74%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Nov 27 Nov 27 Nov 29 Nov 01 Dec 02 Dec 02 Dec 03 Dec 03 Dec 03 Dec 10 Dec 13 Dec
CYAD Celyad $24.88 -1.32 (-5.04%) , BLUE Bluebird Bio $128.38 4.38 (3.53%) … 04:55 11/27/18 11/27 04:55 11/27/18 04:55 Conference/Events	William Blair biotech analysts to hold an analyst/industry conference call » Biotech Analysts, along… Biotech Analysts, along with Dr. Marco Davila of Moffitt Cancer Center, discuss the development of cell therapies in hematological malignancies on an Analyst/Industry conference call to be held on November 27 at 11 am. CYAD Celyad $24.88 -1.32 (-5.04%) BLUE Bluebird Bio $128.38 4.38 (3.53%) NVS Novartis $89.00 -0.74 (-0.82%) GILD Gilead $66.96 0.33 (0.50%) CELG Celgene $68.01 1.11 (1.66%) AUTL Autolus Therapeutics $40.57 -3.69 (-8.34%) ALLO Allogene Therapeutics $27.59 1.09 (4.11%) CLLS Cellectis $21.29 0.17 (0.80%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	27 Nov 27 Nov 27 Nov 29 Nov 01 Dec 02 Dec 02 Dec 03 Dec 03 Dec 03 Dec 10 Dec 13 Dec
CYAD Celyad $26.97 (0.00%) , BLUE Bluebird Bio $116.82 0.55 (0.47%) … 11:11 11/21/18 11/21 11:11 11/21/18 11:11 Conference/Events	William Blair biotech analysts to hold an analyst/industry conference call » Biotech Analysts, along… Biotech Analysts, along with Dr. Marco Davila of Moffitt Cancer Center, discuss the development of cell therapies in hematological malignancies on an Analyst/Industry conference call to be held on November 27 at 11 am. CYAD Celyad $26.97 (0.00%) BLUE Bluebird Bio $116.82 0.55 (0.47%) NVS Novartis $88.49 1.51 (1.74%) GILD Gilead $67.04 -0.54 (-0.80%) CELG Celgene $67.69 0.93 (1.39%) AUTL Autolus Therapeutics $42.60 1.4 (3.40%) ALLO Allogene Therapeutics $26.40 0.79 (3.08%) CLLS Cellectis $20.89 0.65 (3.21%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Nov 27 Nov 27 Nov 29 Nov 01 Dec 02 Dec 02 Dec 03 Dec 03 Dec 03 Dec 10 Dec 13 Dec
CYAD Celyad $26.97 (0.00%) 06:00 11/20/18 11/20 06:00 11/20/18 06:00 Conference/Events	Celyad management to meet with William Blair » Meeting to be held in New… Meeting to be held in New York on November 20 hosted by William Blair. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Nov 22 Nov 27 Nov 01 Dec 03 Dec 10 Dec

Over a quarter ago
CYAD Celyad $27.40 0.38 (1.41%) 05:24 11/12/18 11/12 05:24 11/12/18 05:24 Recommendations	Celyad analyst commentary at Piper Jaffray » Celyad price target… Celyad price target lowered to $51 from $74 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff lowered his price target for Celyad to $51 after rolling forward his discount period to 2019. The analyst, however, keeps an Overweight rating on the shares after the company updated solid tumor data from the Think and Shrink studies of CYAD-01. Celyad will report Think data on 12 relapsed/refractory acute myeloid leukemia patients in December, Tenthoff tells investors in a research note. He also believes the company has enough cash to fund its operations through mid-2020. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Nov 27 Nov 01 Dec 03 Dec 10 Dec

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial